Isocarboxazid
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
solriamfetol
Wake-promoting agent
Wake-promoting agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
10 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 10 →
- IsocarboxazidSevereDatabaseDDInter
- LinezolidSevereDatabaseDDInter
- Methylene BlueSevereDatabaseDDInter
- OzanimodSevereDatabaseDDInter
Mechanism
Norepinephrine–dopamine reuptake inhibitor.
Indications
NarcolepsyExcessive sleepiness during night work (Shift-Work Disorder)
Drug interactions
Linezolid
Severe
Database
Clinical effect not specified
Source: DDInter
Methylene Blue
Severe
Database
Clinical effect not specified
Source: DDInter
Ozanimod
Severe
Database
Clinical effect not specified
Source: DDInter
Phenelzine
Severe
Database
Clinical effect not specified
Source: DDInter
Procarbazine
Severe
Database
Clinical effect not specified
Source: DDInter
Rasagiline
Severe
Database
Clinical effect not specified
Source: DDInter
Safinamide
Severe
Database
Clinical effect not specified
Source: DDInter
Selegiline
Severe
Database
Clinical effect not specified
Source: DDInter
Tranylcypromine
Severe
Database
Clinical effect not specified
Source: DDInter
2 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Hypertensive disorders of pregnancy
FOGSI · Obstetrics & Gynaecology · 2019
Substance use disorders
NIMHANS · Psychiatry · 2022
Alcohol use disorder
MOHFW · Psychiatry · 2021
Generalised anxiety disorder and panic disorder
NICE · Psychiatry · 2020
Chronic kidney disease — mineral and bone disorder
KDIGO · Nephrology · 2017
Other Unclassified drugs
Ask House about solriamfetol
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Harrison 22e·Verified: 2026-05-10 · House clinical team